Fusion Pharmaceuticals
5 known investors
Fusion Pharma develops targeted alpha therapeutics for cancer treatment using proprietary linker technology to connect alpha-emitting medical isotopes to cancer-targeting molecules, delivering lethal damage to tumor cells while minimizing toxicity to healthy tissues.
BiotechHealthtechMedical Devices
Investors · 5
In the news
- Fusion Pharma fetches $213m in IPO - Global Venturingglobalventuring.com · 2020
- Hamilton's Fusion Pharmaceuticals Raises $26 Million CAD - Innovation Factoryinnovationfactory.ca · 2020
- Precision oncology startup Fusion Pharmaceuticals raises $26 million CAD | BetaKitbetakit.com · 2020
- Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing - HealthCaphealthcap.eu · 2019
- Fusion Pharmaceuticals Secures Additional $21M; Closes $46M Series A financing - FinSMEsfinsmes.com · 2017
- Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments - Fusion Pharmafusionpharma.com · 2017